Using targeted radiation therapy for prostate cancer that resists standard treatment
Official title: Stereotactic Ablative Radiotherapy for Oligoprogressive Metastatic Castration-Resistant Prostate Cancer During Abiraterone Therapy
Run by Sunnybrook Health Sciences Centre · NCT04838899 · Data updated 2026-11-12
This study is testing a new type of targeted radiation therapy for men with prostate cancer that isn't responding to standard treatment, to see if it can help control their cancer while they continue their current medication.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 30 (estimated) |
| Sponsor | Sunnybrook Health Sciences Centre Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | July 16, 2016 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | April 12, 2024 |
| Trial ID | NCT04838899 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men with metastatic castration-resistant prostate cancer who are currently on abiraterone and have evidence of oligoprogression.
✕Probably not a fit
Patients with widespread clinical progression or those requiring immediate aggressive treatment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the use of stereotactic ablative body radiotherapy (SABR) to treat oligoprogressive metastatic prostate cancer in patients who are already receiving abiraterone therapy. The approach aims to locally ablate progressing metastatic tumors while allowing the patient to continue their current systemic therapy, potentially delaying the need for more aggressive treatments. By focusing on a limited number of progressing lesions, the study seeks to improve progression-free survival and overall patient outcomes. The trial will evaluate the effectiveness of this method in a population with limited treatment options.
Why it matters
Potential benefit: If successful, this approach could help patients maintain their current treatment longer and improve their quality of life.
How similar studies have gone: While there is limited evidence for this specific approach in prostate cancer, similar strategies have shown promise in other cancer types like renal cell and non-small cell lung cancer.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ECOG performance status 0-1. * Histologic confirmation of prostate adenocarcinoma. * Documentation of metastatic, castration-resistant prostate cancer. * Patient being treated with abiraterone. * Evidence of oligoprogression (according to RECIST \[V1.1\] and/or Prostate Cancer Working Group criteria \[PCWG3\], as applicable), applying any of the following: (i) ≤ 5 metastatic lesions progressing on conventional imaging (≤ 3 progressing metastases in any one organ system) while all other metastases are controlled or responding; (ii) PSA progression only, but in the setting of oligometastases (≤ 5 metastatic lesions seen on imaging, with ≤ 3 metastases in any one organ system); in this setting, all metastases will be irradiated. * All metastases of interest amenable to SABR. Exclusion Criteria: * Patients presenting with unequivocal clinical progression, defined as one of the following: (i) cancer pain requiring the initiation of opioid therapy; (ii) immediate need for cytotoxic chemotherapy as per treating physician's discretion; or (iii) deterioration of performance status to grade ≥ 3 according to ECOG. * Evidence of spinal cord compression. * Prior malignancy within the past 5 years, excluding non-melanoma skin cancer, and in-situ cancer.
Where it's running
-
Odette Cancer Centre
Toronto, Ontario, Canada Recruiting
Study contacts
- Study coordinator: Urban Emmenegger, MD
- Email: urban.emmenegger@sunnybrook.ca
- Phone: +416-480-4928
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treatment for prostate cancer with limited metastasis
This study is testing whether a new treatment for prostate cancer with a few spreading spots can help patients live longer by comparing radiotherapy to surgery.
-
MRT-2359 plus apalutamide in advanced prostate cancer
This Phase 2 trial tests whether taking MRT-2359 with apalutamide can lower PSA in men with castration-resistant prostate cancer.
-
JANX014 for metastatic castration-resistant prostate cancer
This trial will test whether JANX014 is safe, how your body handles it, and whether it shows signs of benefit in adults with metastatic castration-resistant prostate cancer who have already had anti-androgen therapy and typically a taxane.
-
IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7
This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.
-
Terbium‑161 RAD402 treatment for castration‑resistant prostate cancer
This will test a radioactive antibody called 161Tb‑RAD402 to see if it is safe and can help men with castration‑resistant prostate cancer whose disease has progressed after prior treatments.
-
DCC-2812 in advanced kidney, bladder, and castration-resistant prostate cancers
This trial will test whether the oral drug DCC-2812 is safe and shows early signs of benefit for people with advanced kidney (renal cell), bladder (urothelial), or castration-resistant prostate cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.